2014
DOI: 10.1186/1742-6405-11-16
|View full text |Cite
|
Sign up to set email alerts
|

German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients

Abstract: BackgroundCurrent German and European HIV guidelines recommend early evaluation of HCV treatment in all HIV/HCV co-infected patients. However, there are still considerable barriers to initiate HCV therapy in everyday clinical practice. This study evaluates baseline characteristics, “intention-to-treat” pattern and outcome of therapy of HCV/HIV co-infected patients in direct comparison to HCV mono-infected patients in a “real-life” setting.MethodsA large, single-center cohort of 172 unselected HCV patients seen… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

2
9
0

Year Published

2014
2014
2020
2020

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 11 publications
(11 citation statements)
references
References 33 publications
(46 reference statements)
2
9
0
Order By: Relevance
“…Reported cure rates of 32.4% for genotype 1 and 4, and 69.0% for genotype 2 and 3 are in line with findings from the Swiss HIV Cohort Study (35.2% and 68.4%) 9 and other European studies (31–37.5% and 62.5–87%, respectively), 14,19 and comparable to randomised controlled trials (between 17–29% and 44–62%). 24,25 For pegylated interferon treatment, SVR rates of HIV/HCV co-infected patients are lower than those among HCV mono-infected patients.…”
Section: Discussionsupporting
confidence: 87%
See 1 more Smart Citation
“…Reported cure rates of 32.4% for genotype 1 and 4, and 69.0% for genotype 2 and 3 are in line with findings from the Swiss HIV Cohort Study (35.2% and 68.4%) 9 and other European studies (31–37.5% and 62.5–87%, respectively), 14,19 and comparable to randomised controlled trials (between 17–29% and 44–62%). 24,25 For pegylated interferon treatment, SVR rates of HIV/HCV co-infected patients are lower than those among HCV mono-infected patients.…”
Section: Discussionsupporting
confidence: 87%
“…14,18,19 Treatment uptake in Australian co-infected patients was also substantially higher than the 15% or less in the majority of US studies. 10 This may reflect improving treatment options for HCV over time, with our data being more recent than these other studies.…”
Section: Discussionmentioning
confidence: 80%
“…In both surveys, most treated patients had received the best combination of pegylated interferon and ribavirin. A sustained virological response rate of 50% was noted in the 2013 survey, a figure close to that obtained in other studies in co-infection [44] as well as in HCV mono-infection. Liver transplantation has been approached with caution in HIV-HCV co-infected patients with end-stage liver disease because of concern over the sequelae of immunosuppression and ART-related hepatotoxicity.…”
Section: Discussionsupporting
confidence: 87%
“…Of these, 39 (27%) were treated early within 6 months after first HCV diagnosis. [16], and in a German and Swedish HIV/HCV cohort treatment rates were 40% and 25%, respectively [17,18]. In a large US cohort of veterans only 12% of monoinfected patients received therapy between 2000 and 2005 [19]; in coinfected populations treatment uptake was even lower [20,21].…”
Section: Hcv Treatment Uptakementioning
confidence: 92%